1. Kollef MH. Ventilator-associated pneumonia:the role of emerging therapies and diagnostics. Chest, 2015, 147:1448-1450.
[2]
2. Bouadma L, Sonneville R, Garrouste-Orgeas M, et al. Ventilator-associated events:prevalence, outcome, and relationship with ventilator-associated pneumonia. Crit Care Med, 2015, 43:1798-1806.
[3]
3. Tseng CC, Liu SF, Wang CC, et al. Impact of clinical severity index, infective pathogens, and initial empiric antibiotic use on hospital mortality in patients with ventilator-associated pneumonia. Am J Infect Control, 2012, 40:648-652.
[4]
4. Kennedy TP, Nelson S. Hyperoxia, HMGB1, and ventilator-associated pneumonia:reducing risk by practicing what we teach. Am J Respir Cell Mol Biol, 2013, 48:269-270.
[5]
5. Kalanuria AA, Fellerman D, Nyquist P, et al. Variability in diagnosis and treatment of ventilator-associated pneumonia in neurocritical care patients. Neurocrit Care, 2015, 23:44-53.
8. Mishra SB, Azim A, Muzzafar SN. Prevention of ventilator-associated pneumonia and ventilator-associated conditions. Crit Care Med, 2015, 43:e527-e528.
[9]
9. Wang H, Ward MF, Sama AE. Targeting HMGB1 in the treatment of sepsis. Expert Opin Ther Targets, 2014, 18:257-268.
[10]
10. Magna M, Pisetsky DS. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol Med, 2014, 20:138-146.
[11]
11. Liu XX, Yu DD, Chen MJ, et al. Hesperidin ameliorates lipopolysaccharide-induced acute lung injury in mice by inhibiting HMGB1 release. Int Immunopharmacol, 2015, 25:370-376.
[12]
12. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia:prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med, 2003, 31:676-682.
[13]
13. Gul G, Senay D. Value of APACHEⅡ, SOFA and CPIS scores in predicting prognosis in patients with ventilator-associated pneumonia. Respiration, 2006, 73:503-508.
